Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMG-20

            Therapeutic Area: Dermatology Product Name: IMG-20

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vertex Ventures

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing November 09, 2020

            Details:

            The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials for multiple indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            CBP-201 is a potent monoclonal antibody against IL-4Rα. Data support further evaluation of CBP-201’s effects in an ongoing dose-ranging study in patients with moderate-to-severe AD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SHR0302

            Therapeutic Area: Dermatology Product Name: SHR0302

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            The study conducted in ten sites in Australia and New Zealand, evaluated the efficacy and safety of CBP-201 in 31 patients with moderate-to-severe AD who have had inadequate response to topical corticosteroids and immunosuppressants.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $115.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing August 24, 2020

            Details:

            The company plans to use the proceeds to support the ongoing Phase 2 clinical trial for CBP-201; Phase 2 trials of CBP-307; expand the CBP-201 clinical development program into additional indications; and to support planned Phase 3 trials of CBP-201 and CBP-307.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.